2,644
Views
11
CrossRef citations to date
0
Altmetric
Position Papers

Emergency Medical Services Management of ST-Elevation Myocardial Infarction

, MD, MPH, , MD, MHSc, , MD, MSc, , DO, , DO, , MD & , MD show all
Pages 395-403 | Received 19 Feb 2008, Accepted 19 Feb 2008, Published online: 02 Jul 2009

Introduction

According to data published by the American Heart Association (AHA), the annual incidence of acute myocardial infarction (AMI) in the United States approximates 850,000, resulting in over 150,000 deaths per year.Citation1 The emergency medical services (EMS) system plays a significant role in the management of AMI with respect to caring for those who access the health care system via EMS andalso in administering public educational programs to encourage early access via EMS.

It is generally well accepted that early reperfusion is the primary goal of therapy for patients having an acute ST-segment-elevation myocardial infarction (STEMI).Citation2, Citation3 Because many patients access the health care system via EMS, EMS providers are well positioned to facilitate achieving the goal of early reperfusion throughout the community.Citation4 Consequently, the National Association of EMS Physicians (NAEMSP) has developed a position statement on the role of EMS in the management of the STEMI patient andthe development of cardiovascular systems of care.Citation5

The NAEMSP believes that advanced life support EMS providers should have the education, appropriate training, equipment, andprotocols to facilitate early identification andthe initial care of patients with STEMI. These protocols should address the appropriate use of 12-lead electrocardiograms (ECGs) to facilitate early diagnosis of STEMI andinitiation of pathways to ensure early definitive reperfusion. EMS systems should be integrated to 18.6pt with regional cardiac care programs andparticipate in developing these systems. Such reperfusion strategies may include a variety of methods of early reperfusion, from prehospital fibrinolytics to primary transportation for percutaneous coronary intervention (PCI). In addition to meeting the goal of early reperfusion, EMS providers have a role in the appropriate management of the STEMI patient with other adjunctive therapies. This paper highlights the important components of the NAEMSP position statement andthe supporting science behind the statement.

Early Identification of the STEMI Patient

To achieve an optimal outcome, it is critical to consider the role of public education andearly activation of EMS. Patients' andbystanders' recognition of the signs andsymptoms of an AMI andtheir willingness to activate the EMS system impact the time to reperfusion therapy. With each 30-minute increment in delay to reperfusion, one-year mortality increases by 7.5%.Citation6 In the United States, median delay from onset of symptoms to hospital arrival ranges from 1.5 to 6 hours.Citation7 Similar delay trends exist in other countries as well.Citation8, Citation9, Citation10

Several factors have been implicated in the delay of symptom recognition andaccess, including sociodemographic (female, minority, older age, fewer years of education, lower income), clinical (history of diabetes), social (consultation with family, consultation with family physician), patient appraisal (minimizing), andemotional (concern about troubling others, being embarrassed about seeking help, living alone) factors.Citation9 Unfortunately, general public awareness andeducational campaigns have not been shown to have an effect on minimizing delays in accessing the health care system.Citation11 Once AMI patients decide to access medical care, a substantial number of them do not call EMS, even though the use of EMS andsubsequent hospital prenotification have been shown to reduce time delay to reperfusion.Citation12, Citation13, Citation14

Once the patient has accessed the EMS system, it is important that EMS providers perform an appropriate history andphysical examination to evaluate for acute coronary syndromes. EMS providers are often taught that the chief complaint for a patient having an AMI is chest pain. While this is often the case, chest pain is not always the chief complaint.Citation15 Therefore, in order to avoid missing a potential STEMI, the EMS provider should also ask the patient about other anginal equivalents, including dyspnea, palpitations, syncope, andfatigue.Citation15, Citation16 Clinical presentations of STEMI with symptoms other than chest pain are frequent in diabetic patients, female patients, andelderly patients. Chest discomfort with evidence of diaphoresis significantly increases the likelihood for AMI or unstable angina.Citation17 Other physical findings associated with STEMI may include abnormal vital signs or lung sounds consistent with heart failure.

Utility of the Electrocardiogram

Beyond the identification of the potential STEMI patient through appropriate history andphysical examination, EMS providers have a role in making the definitive diagnosis of STEMI through the acquisition andinterpretation of a 12-lead ECG andsubsequent advance hospital notification. The AHA recommends implementation of out-of-hospital 12-lead ECG diagnostic programs in urban andsuburban EMS systems as a Class I recommendation.Citation18 In a recent meta-analysis, the average 1.2 minutes of extra time that the paramedics took on scene to complete an ECG led to an average of 36.1 minutes of savings in door-to-needle time.Citation19

However, despite the strength of evidence supporting prehospital ECGs in reducing both door-to-needle anddoor-to-balloon times, many communities do not fully take advantage of this technology. Some EMS systems simply do not have 12-lead ECG devices. Others may have appropriate devices, but do not use them consistently or lack the ability to convey the information to local emergency departments (EDs). Urban andsuburban EMS systems should prioritize acquiring andimplementing effective prehospital 12-lead ECG diagnostic programs.

Once the EMS provider has acquired the 12-lead ECG, the tracing will need to be interpreted to determine if the patient is having a STEMI. The two primary options for interpretation of the 12-lead ECG are interpretation directly by the EMS provider (either independently or aided by the 12-lead device's interpretation software) andinterpretation by a physician after transmission of the ECG to the physician via a communication device. Based on review of the available literature, there is no clear answer regarding which option results in the best outcome in terms of both patient mortality andresource allocation for the health care system. EMS system medical directors andadministrators will need to consider local circumstances to determine the appropriate method of ECG interpretation for the potential STEMI patient.

In order for a prehospital 12-lead ECG program to be successful, the EMS system must allow for the acquisition andinterpretation of the 12-lead ECG, the appropriate transport policies that match the detected prehospital pathology with the receiving hospital's capability to care for the patient, communication of the information to clinicians at the receiving hospital, andpolicies to utilize the information provided by the EMS system to expedite care upon arrival at the hospital.

Once the potential STEMI patient has been identified by EMS personnel, the providers should complete a reperfusion checklist during transport (including inclusion/exclusion criteria for either fibrinolysis or PCI) andrelay this information to the receiving hospital.Citation20, Citation21

Standard Therapies for STEMI

Cardiac Monitor

Patients experiencing AMI are at high risk for potentially life-threatening arrhythmias. In 1968, Adgey et al. reported 335 of 550 patients (61%) having significant bradyarrhythmia in posterior myocardial infarctions.Citation22 More recently, Scrutinio et al. found an incidence of 52% of patients having serious ventricular arrhythmias during the initial phase of STEMI.Citation23 In addition, Swart et al. found that 55.6% of EMS patients with atrioventricular block were having AMI.Citation24 Therefore, all patients identified as having STEMI should be placed on a cardiac monitor andcontinuously evaluated for life-threatening arrhythmias.

Intravenous Access

Because of the high risk of malignant arrhythmia andthe potential need to treat the patient with antiarrhythmic medications and/or medications for acute heart failure, EMS providers should attempt to establish peripheral intravenous access in all STEMI patients. However, while EMS providers have certainly established proficiency at placement of peripheral intravenous lines, attempts prior to transport can extend the overall out-of-hospital time.Citation25, Citation26 Therefore, if the providers are not able to quickly establish intravenous access, attempts should be aborted until the patient is in transport. Further attempts can be done while in transport.

Oxygen

While supplemental oxygen is routinely used by EMS providers in the management of AMI, there is no clear evidence that oxygen actually has a beneficial effect in the management of the STEMI patient. In fact, some have suggested that oxygen may be harmful because of a theoretical effect of causing vasoconstriction andresultant decrease in coronary supply.Citation27, Citation28 However, others have demonstrated that oxygen therapy can reduce both angina andischemia.Citation29, Citation30 Therefore, patients who are hypoxemic (i.e., oxygen saturation less than 90%) should have administration of oxygen as necessary to correct the hypoxemia. Furthermore, it is reasonable to provide low-flow oxygen therapy by nasal cannula for those patients who are not hypoxemic. However, 100% oxygen therapy with a non-rebreather mask is not recommended unless necessary to correct hypoxemia.

Aspirin

A significant component of the pathophysiology of disease of AMI is clot formation andplatelet aggregation.Citation31, Citation32 Barbash et al. found that those patients treated with prehospital aspirin had better outcomes.Citation33 While there may be a theoretical adverse effect if the patient is having an aortic dissection with a coexisting STEMI, this has not been scientifically demonstrated. Therefore, antiplatelet therapy should be at the forefront of the management of the STEMI patient andadministered by EMS personnel as soon as possible. The only absolute contraindication andrisk for aspirin therapy is with a patient who has a true anaphylactic allergic reaction to aspirin or other salicylates.

Nitroglycerin

Acting as a vasodilator, nitroglycerin can be helpful in reducing angina as well as decreasing cardiac workload. Nitroglycerin can increase the perfusion of the diseased subendocardial regions of the heart as well as decrease both preload andafterload.Citation34, Citation35 Therefore, nitroglycerin has long been used as standard therapy in the management of the AMI patient andshould still be considered as part of first-line therapy.Citation36, Citation37 However, it should also be understood that the benefit of nitroglycerin is in the management of a patient's symptoms andnot in reversal of the cause of the infarction. Therefore, whereas nitroglycerin may be helpful in the management of the STEMI patient, it should not be given a higher priority over treatment modalities that will help to reverse the underlying pathology such as aspirin. Furthermore, because nitroglycerin can cause a precipitous drop in a patient's blood pressure, EMS providers should use nitrates with caution.

Opiates

Because of concerns that treatment with morphine may be associated with worse outcomes for non-STEMI patients, there has been some controversy regarding the use of morphine in the setting of AMI.Citation38 However, as the only study demonstrating this association has significant study design issues, there is no definitive evidence that morphine or other opiates such as fentanyl are harmful to the AMI patient. Therefore, because the evidence that morphine may be harmful is weak, it is reasonable to treat pain associated with STEMI with opiates.

Choice of Reperfusion Strategy

All patients with chest pain andST-segment elevation on the initial ECG should be considered candidates for early reperfusion.Citation18

There is evidence from a number of randomized controlled trials showing that primary PCI is superior to fibrinolysis for reperfusion in acute STEMI. Keeley et al. published a systematic review andmeta-analysis of 23 trials demonstrating that patients who received primary PCI had lower rates of short-term mortality (odds ratio [OR] 0.70; 95% confidence interval [CI] 0.58–0.85), nonfatal reinfarction (OR 0.35; 95% CI 0.27–0.45), andstroke (OR 0.46; 95% CI 0.30–0.72).Citation2 However, since timely access to primary PCI is often problematic in certain geographic locations, fibrinolytics are often the treatment modality of choice. The major advantages of fibrinolytics are wide availability, rapid administration, andoperator independence (i.e., the benefit of therapy does not depend on the skill of the operator as is the case with primary PCI).Citation39

Several disadvantages to fibrinolytic therapy must also be considered. First, approximately 20–30% of all STEMI patients who present within 12 hours after symptoms have contraindications to fibrinolysis.Citation40, Citation41 In the 2005 AHA emergency cardiovascular care guidelines, which were based on the 2005 International Liaison Committee on Resuscitation (ILCOR) Consensus on Science, absolute contraindications for fibrinolysis include prior intracranial hemorrhage, known structural cerebral vascular lesion (e.g., arterio-venous malformation [AVM]), known malignant intracranial neoplasm, ischemic stroke within three months (except acute ischemic stroke within three hours), suspected aortic dissection, active bleeding or bleeding diathesis, andsignificant closed head trauma or facial trauma within three months.Citation18 Second, fibrinolysis fails in up to 24% of patients,Citation42, Citation43, Citation44 andthird, approximately 25% of patients receiving a fibrinolytic agent will have a reinfarction within three months after the initial event.Citation45

According to the most recent American College of Cardiology/American Heart Association (ACC/AHA) recommendations, an invasive strategy is generally preferred if symptom onset to medical contact is greater than three hours, skilled primary PCI facilities are available with surgical backup, medical contact-to-balloon or door-to-balloon time can be achieved in less than 90 minutes, anddoor-to-balloon time minus door-to-needle time (the delta time) can be achieved in less than 60 minutes.Citation46 In addition, PCI is preferred if there are contraindications to fibrinolysis, there is an increased risk of bleeding, the patient has a “high-risk STEMI,” or the diagnosis of STEMI is in doubt. A “high-risk STEMI” is defined as STEMI with associated cardiogenic shock. It should be noted that the goal of performing PCI within 90 minutes after the first medical contact represents the longest time that should be considered, rather than the ideal time frame.Citation47 Moreover, recent evidence suggests that acceptable reperfusion delay (i.e., the difference between time to balloon andtime to drug) varies considerably depending on patient age, symptom duration, andinfarct location.Citation48

Fibrinolytic therapy may be preferred in patients whose first medical contact is less than three hours when PCI is not immediately available,Citation49, Citation43, Citation44, Citation45, Citation46, Citation47, Citation48, Citation49, Citation50, Citation51 especially in those who seek medical therapy within one hour after the onset of symptoms, as there is some evidence that very early fibrinolysis may abort the infarction.Citation39

Regardless of the timing of the onset of symptoms, because of improved outcomes with an invasive strategy, patients who are in cardiogenic shock and/or those with acute congestive heart failure should be considered for either direct or secondary transfer to a center that has the capabilities for PCI if the invasive strategy can be performed within 18 hours after the onset of shock.Citation52, Citation53, Citation54 Furthermore, it is reasonable to consider secondary transfer if primary PCI can be achieved within 90 minutes from the time that the patient arrives at the primary hospital.Citation50, Citation55 However, according to data from the National Registry of Myocardial Infarction (NRMI), the median time from presentation at the first hospital to PCI at the second hospital in the United States is 180 minutes,Citation56 which greatly exceeds the current recommendations for 90-minute medical contact-to-balloon interval.

For those patients who are given fibrinolytics anddo not have resolution of symptoms or ST elevations within 90 minutes, rescue PCI should be performed immediately.Citation57, Citation58 However, facilitated PCI (half- or full-dose fibrinolytics followed by planned PCI) has not been shown to be helpful andis generally not recommended.Citation59

Finally, because there is a diminished advantage of PCI when the delta time exceeds 60 minutes, andprehospital fibrinolysis has been demonstrated to be relatively safe andefficacious,Citation60, Citation61 the AHA guidelines support the use of prehospital fibrinolytics for those patients who do not have contraindications andhave a transport time greater than 60 minutes.Citation18

Prehospital Fibrinolytics

A number of randomized clinical trials have shown that prehospital fibrinolytics can significantly decrease the time from symptom onset to reperfusion treatment when compared with ED fibrinolysis.Citation60, Citation61, Citation62, Citation63 In general, prehospital fibrinolysis compared with ED fibrinolysis is associated with a reduction of 45–60 minutes in the delay to treatment andis associated with a significant reduction in mortality.Citation61

The benefit of prehospital fibrinolysis has been shown in large registry data sets. Using data from a registry of 13,158 patients in Sweden, Bjorklund et al. compared patients who were given prehospital fibrinolytics (PHT) with those STEMI patients who were transported by EMS andwere given fibrinolytics on ED arrival (IHT). They found that there was a 52-minute time savings in time to treatment (median time to treatment: PHT 113 min, IHT 165 min) anda 29% reduction in the odds of death at 12 months (OR 0.71; 95% CI 0.55–0.92).Citation64 In Canada, during the Assessment of the Safety andEfficacy of a New Thrombolytic Regimen (ASSENT) III Plus Prehospital Lysis Trial, a registry of all concurrent myocardial infarctions was documented.Citation65 The median times to fibrinolysis treatment were 103 minutes in the prehospital fibrinolysis cohort, 158 minutes for in-hospital fibrinolysis for ambulatory patients who arrived at the ED without EMS, and163 minutes for in-hospital fibrinolysis for patients who arrived by ambulance. Prehospital fibrinolysis led to 55-minute and60-minute time savings, respectively.Citation65

The United Kingdom has successfully implemented a countrywide prehospital fibrinolysis program.Citation66 The Fifth Public Report on the Treatment of Heart Attack Patients from the Myocardial Infarction National Audit Project (MINAP) presents data from all hospitals andambulance services in England andWales that provided care for patients with suspected heart attack from April 2005 to March 2006 (2005–2006) in comparison with data from the previous year (2004–2005).Citation67 The report shows that fibrinolytic treatment is increasingly being given by paramedics before the patient reaches the hospital, reducing the time to treatment. Twenty-eight of the 31 ambulance services in England andthe Welsh ambulance service now give fibrinolytic treatment to patients before they reach the hospital. In 2005–2006, 2,231 patients received prehospital fibrinolytic treatment, compared with 1,374 patients in 2004–2005. Currently, 83% of eligible patients in England receive thrombolytic treatment within 30 minutes after arrival at the hospital, compared with 44% during early 2001.Citation68 This is also reflected in other registry data sets across the globe.Citation69, Citation70 Prehospital fibrinolysis is a growing andfeasible option globally, particularly in those centers without timely access to cardiac catheterization facilities.

Randomized controlled trials andregistry data support the safety andefficacy of prehospital fibrinolysis for patients with STEMI.Citation47 Inappropriate or unjustified administration of fibrinolytics to patients who do not have a STEMI will always be a risk, but contemporary data demonstrate low rates compared with the rates for in-hospital treatment.Citation71 Because there are a few reports of patients having an aortic dissection coexisting with an AMI,Citation72 clinical scenarios suggestive of dissection should be incorporated into prehospital fibrinolysis training programs. Nevertheless, with appropriate training, EMS providers should be able to safely administer prehospital fibrinolytics when indicated—i.e., when treating patients who have long transport times and/or patients who present very early in the time course of their STEMI (especially within two hours after symptom onset).Citation39, Citation49, Citation73, Citation74, Citation75, Citation76, Citation77

Requirements for a Site to Be Considered a Primary PCI Center

According to the ACC/AHA guidelines, an important consideration in the design of EMS destination protocols for primary PCI is the availability of “skilled” PCI facilities with surgical backup. Criteria for skilled facilities include minimum requirements for the facility andminimum requirements for the operator. A skilled PCI facility performs at least 200 PCIs per year,Citation18 of which a minimum of 36 are primary PCIs. A skilled PCI operator is one who performs at least 75 PCIs per year.Citation18 Several analyses have demonstrated a direct relationship between both facility andoperator procedural volume andbetter clinical outcomes with respect to PCI.Citation78 In addition, the percentage of STEMIs treated with primary PCI within a given institution has a positive effect on reducing delay to reperfusion andimproving clinical outcomes.Citation79 In a retrospective analysis of more than 360,000 PCI procedures, it was shown that the in-hospital mortality was 2.56% in low-volume centers (<200 PCI procedures per year), 1.83% in medium-volume centers (200–399/year), 1.64% in high-volume centers (400–999/year), and1.35% in very-high-volume centers (>1,000/year).Citation80 The NRMI-2 registry showed that the mortality of patients who received primary PCI at institutions that performed more than 33 primary PCIs per year had an odds-adjusted mortality that was 33% lower than that for patients in institutions that performed fewer than 12 primary PCIs per year.Citation81

Urgent surgical backup, typically needed for acute coronary artery occlusion occurring during the procedure or for identified coronary artery dissection, is needed for very few patients who receive primary PCI (∼ 0.5–1%).Citation82 However, patients who need emergent surgery are often hemodynamically unstable andmay be difficult to stabilize andtransport. There has been much debate about whether or not on-site surgical backup should be a requirement for primary PCI programs. The ACC/AHA guidelines include a Class IIb recommendation that primary PCI can be performed without on-site surgical backup, provided that the facility andoperator are “skilled,” there is capability at the PCI center for advanced hemodynamic support, andthere is a proven plan for rapid transport to off-site surgical backup.Citation46 Some have suggested that this should be upgraded to a Class IIa recommendation given the accumulated evidence in support of this practice.Citation82 More than 15 registries of patients treated with primary PCI in centers without on-site surgical backup have demonstrated the safety of this approach.Citation82

Prehospital Triage to the PCI Laboratory

Several centers across North America are using paramedics to triage patients directly to the PCI laboratory.Citation83 Henry et al. reported that implementation of a standardized protocol andintegrated transfer system significantly reduced door-to-balloon times.Citation84 In a comprehensive STEMI program in Calgary, Alberta, Canada, investigators describe a collaborative effort in their implementation of a prehospital pathway for accessing the PCI laboratory.Citation83 Their combined efforts resulted in a 3.1% 30-day mortality rate for STEMI patients.Citation83 The dynamic partnership involving medical personnel andEMS focused on the prehospital diagnosis of STEMI andthe subsequent activation of the PCI laboratory. Through intensive multidisciplinary collaboration, their pathway achieved door-to-balloon times of less than 60 minutes and90 minutes in 49% and79% of patients, respectively.Citation83 This study was conducted in a large urban Canadian city with a contemporary EMS system anda leading national PCI program. Le May et al. compared door-to-balloon times for patients referred to PCI directly from the field by specially trained paramedics andpatients referred to PCI by outside EDs.Citation85 Patients referred by the specially trained paramedics had shorter median door-to-balloon times (69 minutes compared with 123 minutes; p < 0.001) anda higher percentage of door-to-balloon times of less than 90 minutes (79.7% compared with 11.9%; p < 0.001).Citation85 Therefore, EMS medical directors should consider direct admission to the PCI laboratory from the out-of-hospital environment if local capabilities support this approach.

Other Therapies to Consider

Clopidogrel (Plavix)

Clopidogrel, an adenosine diphosphate receptor antagonist, has activity in inhibiting the activation andaggregation of platelets.Citation86 Sabatine et al. randomly assigned patients to clopidogrel or placebo prior to in-hospital fibrinolysis followed by angiography anddemonstrated a reduction of the composite endpoint of death from cardiovascular causes, recurrent myocardial infarction, or recurrent ischemia (OR 0.64; 95% CI 0.53–0.76), without an increased risk of major bleeding.Citation87 Other authors have found similar or equivocal results in outcomes, also without an increased risk of bleeding.Citation88, Citation89 In the use of clopidogrel andfibrinolysis compared with placebo andfibrinolysis for the prehospital management of STEMI, Verheugt et al. found equivocal results without an increased risk of bleeding.Citation90 Therefore, although the scientific evidence does not demonstrate a clear benefit to clopidogrel in the prehospital environment, some EMS systems may consider its use for the treatment of the STEMI patient.

Quality Assurance

In developing a system for the management of STEMI patients, EMS medical directors andadministrators should establish a program of quality assurance andquality improvement (QA/QI). This system should begin with the training of EMS providers in the recognition, assessment, anddiagnosis of the STEMI patient. The QA/QI program should include the development of a regional STEMI database that can be used to correlate care delivered with patient outcomes. Finally, regular review of the system should be performed andimprovement should be based on findings as recorded in the database.

Integration of the EMS System with Community andRegional Cardiac Systems of Care

In order to maximize the care of STEMI patients, EMS providers should receive regular continuing education in the identification andmanagement of STEMI patients. This should include understanding the typical andatypical presentations of acute coronary syndromes, as well as interpretation of 12-lead ECGs.

Once STEMI patients are identified, EMS providers should communicate early with receiving hospitals so that these hospitals are prepared for patient arrival. Some systems may even adopt the model of direct transport from the field to the catheterization laboratory, bypassing the ED.

The choice of reperfusion strategy andthe method to deliver this strategy will be determined by a combination of the evolving science andlocal circumstances. In general, some guidelines for the appropriate strategy are as follows:

  1. The prehospital 12-lead ECG is the cornerstone for optimized care of the STEMI patient throughout the community. Every urban andsuburban EMS system should prioritize the implementation of effective prehospital 12-lead ECG diagnostic programs. In fact, NAEMSP encourages rural EMS systems to also utilize 12-lead ECG programs for the early diagnosis of STEMI.

  2. All STEMI patients who present to the health care system within 12 hours after symptom onset should be considered for early reperfusion. In addition, patients in cardiogenic shock should be considered for early reperfusion in the first 18 hours after the onset of symptoms.

  3. For patients who present within three hours after symptom onset, it is not fully known if PCI is superior to fibrinolytics. However, when the provider is given an equal choice, it is reasonable to choose PCI because of the lower risk of reinfarction andsignificant bleeding.

  4. For patients who present between three and12 hours after the onset of symptoms, PCI is the superior choice of reperfusion strategy. However, the advantages of PCI over fibrinolytics diminish with a medical contact-to-balloon time of more than 90 minutes or a 60-minute delay beyond the time that fibrinolytics could have been given. Therefore, if these times are expected to exceed 90 minutes or 60 minutes, respectively, fibrinolytics may be the preferred option.

  5. When considering primary transport to a center capable of PCI vs. transport to the closest facility, the EMS system should be designed in such a manner as to account for the relationship between the timing of symptoms andthe available treatment modalities. It may be beneficial to transport a patient to a PCI-capable center if the difference in transport time does not exceed the time window of 90 minutes from the time at which the patient could have presented to the closest hospital compared with the balloon time at the PCI-capable center. This consideration would also be the case (and would be even more difficult to accomplish) for those patients who are cared for initially at a non-PCI center andthen transferred to a PCI center for the purpose of primary PCI.

  6. For those systems that have a transport time greater than 60 minutes, prehospital fibrinolytics should be considered.

Regardless of the chosen treatment strategy, it is obvious that the best care will be achieved only with a systematic approach. Jollis et al. demonstrated that with the development of a coordinated approach, reperfusion times improve.Citation91 With the implementation of a statewide system to facilitate early reperfusion, median times to reperfusion for patients presenting to PCI hospitals improved from 85 minutes to 74 minutes (p < 0.001), andmedian reperfusion times for patients transferred to PCI hospitals improved from 165 minutes to 128 minutes (p < 0.001).Citation91 Therefore, early reperfusion is best achieved with a coordinated effort of the EMS system, the EDs, andthe cardiovascular services within a given hospital andregional health care system.

Future Research

It is important to recognize that the science of the EMS management of STEMI is in continuous evolution. Therefore, the recommendations of this paper should be taken in the context of the published literature available at the time of writing. Future studies should focus on the effects of physician vs. paramedic interpretation of 12-lead ECGs, direct transport to the catheterization laboratory from the field, bypass of the closest hospital to a PCI center, andthe use of other adjunctive agents by EMS providers such as clopidogrel andthe glycoprotein IIb/IIIa inhibitors.

Conclusion

EMS medical directors andadministrators should work together with the local health care system to develop a coordinated approach to the STEMI patient. EMS providers should focus on early identification of the STEMI patient andsubsequent notification to the receiving hospital. The system should be designed to maximize achieving treatment time goals of less than 30 minutes for first medical contact or door to fibrinolytic administration, andless than 90 minutes for first medical contact or door to inflation of catheterization balloon.

References

  • American Heart Association. Heart Disease andStroke Statistics—2007 Update [pamphlet]. 2007. American Heart Association, Dallas, TX 2007
  • Keeley E C, Boura J A, Grines C L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20
  • Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality andmajor morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343: 311–22
  • McGinn A P, Rosamond W D, Goff D C, Jr, Taylor H A, Miles J S, Chambless L. Trends in prehospital delay time anduse of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987–2000. Am Heart J 2005; 150: 392–400
  • National Association of EMS Physicians. Prehospital management of acute myocardial infarction [position paper]. Prehosp Emerg Care 2008; 12: 393–394
  • Deluca G, Suryapranata H, Ottervanger J P, Antman E M. Time delay to treatment andmortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109: 1223–5
  • Moser D K, Kimble L P, Alberts M J, et al. Reducing delay in seeking treatment by patients with acute coronary syndrome andstroke: a scientific statement from the American Heart Association Council on Cardiovascular Nursing andStroke Council. Circulation 2006; 114: 168–82
  • Ratner P A, Tzianetas R, Tu A W, et al. Myocardial infarction symptom recognition by the lay public: the role of gender andethnicity. J Epidemiol Community Health 2006; 60: 606–15
  • Dracup K, McKinley S, Riegel B, Mieschke H, Doering L V, Moser D K. A nursing intervention to reduce prehospital delay in acute coronary syndrome: a randomized clinical trial. J. Cardiovasc Nurs 2006; 21: 186–93
  • Limbu Y R, Malla R, Regmi S R, et al. Public knowledge of heart attack in a Nepalese population survey. Heart Lung 2006; 35: 164–9
  • Luepker R V, Raczynski J M, Osganian S, et al. Effect of a community intervention on patient delay andemergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA 2000; 284: 60–7
  • Kerr D, Holden D, Smith J, Kelly A M, Bunker S. Predictors of ambulance use in patients with acute myocardial infarction in Australia. Emerg Med J 2006; 23: 948–52
  • Canto J G, Zalenski R J, Ornato J P, et al. Use of emergency medical services in acute myocardial infarction andsubsequent quality of care: observations from the National Registry of Myocardial Infarction 2. Circulation 2002; 106: 3018–23
  • Goodacre S, Kelly A M, Kerr D. Potential impact of interventions to reduce times to thrombolysis. Emerg Med J 2004; 21: 625–9
  • Gupta M, Tabas J A, Kohn M A. Presenting complaint among patients with myocardial infarction who present to an urban, public hospital emergency department. Ann Emerg Med 2002; 40: 180–6
  • McSweeney J C, Cody M, O'Sullivan P, Elberson K, Moser D K, Garvin B J. Women's early warning symptoms of acute myocardial infarction. Circulation 2003; 108: 2619–23
  • Hargarten K M, Aprahamian C, Stueven H, Olson D W, Aufderheide T P, Mateer J R. Limitations of prehospital predictors of acute myocardial infarction andunstable angina. Ann Emerg Med 1987; 16: 1325–9
  • 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation andEmergency Cardiovascular Care. Circulation 2005; 112: IV1–203
  • Morrison L J, Brooks S, Sawadsky B, McDonald A, Verbeek P R. Prehospital 12-lead electrocardiography impact on acute myocardial infarction treatment times andmortality: a systematic review. Acad Emerg Med 2006; 13: 84–9
  • Armstrong P W, Bogaty P, Buller C E, Dorian P, O'Neill B J. The 2004 ACC/AHA Guidelines: a perspective andadaptation for Canada by the Canadian Cardiovascular Society Working Group. Can J Cardiol 2004; 20: 1075–9
  • Van d e, Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28–66
  • Adgey A A, Geddes J S, Mulholland H C, Keegan D A, Pantridge J F. Incidence, significance, andmanagement of early bradyarrhythmia complicating acute myocardial infarction. Lancet 1968; 2: 1097–101
  • Scrutinio D, De Toma L, Mangini S G, et al. Ischaemia related ventricular arrhythmias in patients with variant angina pectoris. Eur Heart J 1984; 5: 1013–22
  • Swart G, Brady W J, Jr, DeBehnke D J, Ma O J, Aufderheide T P. Acute myocardial infarction complicated by hemodynamically unstable bradyarrhythmia: prehospital andED treatment with atropine. Am J Emerg Med 1999; 17: 647–52
  • Pace S A, Fuller F P, Dahlgren T J. Paramedic decisions with placement of out-of-hospital intravenous lines. Am J Emerg Med 1999; 17: 544–7
  • Slovis C M, Herr E W, Londorf D, Little T D, Alexander B R, Guthmann R J. Success rates for initiation of intravenous therapy en route by prehospital care providers. Am J Emerg Med 1990; 8: 305–7
  • Kenmure A C, Murdoch W R, Beattie A D, Marshall J C, Cameron A J. Circulatory andmetabolic effects of oxygen in myocardial infarction. Br Med J 1968; 4: 360–4
  • Baron J F, Vicaut E, Hou X, Duvelleroy M. Independent role of arterial O2 tension in local control of coronary blood flow. Am J Physiol 1990; 258: H1388–H1394
  • Brandenburg M A. The utility of oxygen in myocardial infarction. J Emerg Med 2000; 19: 63–5
  • Madias J E, Madias N E, Hood W B, Jr. Precordial ST-segment mapping. 2. Effects of oxygen inhalation on ischemic injury in patients with acute myocardial infarction. Circulation 1976; 53: 411–7
  • Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365–72
  • Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481–8
  • Barbash I M, Freimark D, Gottlieb S, et al. Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration. Cardiology 2002; 98: 141–7
  • Horowitz J D. Role of nitrates in unstable angina pectoris. Am J Cardiol 1992; 70: 64B–71B
  • Parratt J R. Nitroglycerin—the first one hundred years: new facts about an old drug. J Pharm Pharmacol 1979; 31: 801–9
  • Stratton M A. Use of nitrates in patients with acute myocardial infarction. Clin Pharm 1984; 3: 32–9
  • Flaherty J T. Role of nitrates in acute myocardial infarction. Am J Cardiol 1987; 60: 35H–38H
  • Meine T J, Roe M T, Chen A Y, et al. Association of intravenous morphine use andoutcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J 2005; 149: 1043–9
  • Taher T, Fu Y, Wagner G S, et al. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety andEfficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol 2004; 44: 38–43
  • Grzybowski M, Clements E A, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003; 290: 1891–8
  • Juliard J M, Himbert D, Golmard J L, et al. Can we provide reperfusion therapy to all unselected patients admitted with acute myocardial infarction?. J Am Coll Cardiol 1997; 30: 157–64
  • Anderson J L, Karagounis L A, Becker L C, Sorensen S G, Menlove R L. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, andelectrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87: 1829–39
  • Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367: 569–78
  • The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, andsurvival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329: 1615–22
  • Gibson C M, Karha J, Murphy S A, et al. Early andlong-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42: 7–16
  • Antman E M, Anbe D T, Armstrong P W, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588–636
  • Boden W E, Eagle K, Granger C B. Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol 2007; 50: 917–29
  • Pinto D S, Kirtane A J, Nallamothu B K, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114: 2019–25
  • Steg P G, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851–6
  • Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J 2003; 24: 94–104
  • Zahn R, Schiele R, Gitt A K, et al. Impact of prehospital delay on mortality in patients with acute myocardial infarction treated with primary angioplasty andintravenous thrombolysis. Am Heart J 2001; 142: 105–11
  • Antman E M, Anbe D T, Armstrong P W, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588–636
  • Hochman J S, Sleeper L A, White H D, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190–2
  • Hochman J S, Sleeper L A, Webb J G, et al. Early revascularization andlong-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511–5
  • Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000; 21: 823–31
  • Nallamothu B K, Bates E R, Herrin J, Wang Y, Bradley E H, Krumholz H M. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111: 761–7
  • de Winter R J, Windhausen F, Cornel J H, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005; 353: 1095–104
  • Polonski L, Gasior M, Wasilewski J, et al. Outcomes of primary coronary angioplasty andangioplasty after initial thrombolysis in the treatment of 374 consecutive patients with acute myocardial infarction. Am Heart J 2003; 145: 855–61
  • Keeley E C, Boura J A, Grines C L. Comparison of primary andfacilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367: 579–88
  • Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. N Engl J Med 1993; 329: 383–9
  • Morrison L J, Verbeek P R, McDonald A C, Sawadsky B V, Cook D J. Mortality andprehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 283: 2686–92
  • Weaver W D, Cerqueira M, Hallstrom A P, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage andIntervention Trial. JAMA 1993; 270: 1211–6
  • Morrow D A, Antman E M, Sayah A, et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol 2002; 40: 71–7
  • Bjorklund E, Stenestrand U, Lindback J, Svensson L, Wallentin L, Lindahl B. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay andmortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J 2006; 27: 1146–52
  • Welsh R C, Travers A, Senaratne M, Williams R, Armstrong P W. Feasibility andapplicability of paramedic-based prehospital fibrinolysis in a large North American center. Am Heart J 2006; 152: 1007–14
  • National Health Service, United Kingdom, Available at: http://www.replondon.ac/uk/pubs/books/minap06/index.htm Fifth Public Report from the Myocardial Infarction National Audit Project (MINAP). Royal College of Physicians (England andWales). Accessed September 1, 2007
  • National Health Service, United Kingdom, Available at: http://www.replondon.ac.uk/pubs/books/minap06/index.htm Fifth Public Report from the Myocardial Infarction National Audit Project (MINAP). Royal College of Physicians (England andWales). Accessed September 1, 2007
  • National Health Service, United Kingdom, Available at: http://www.replondon.ac/uk/pubs/books/minap06/index.htm Fifth Public Report from the Myocardial Infarction National Audit Project (MINAP). Royal College of Physicians (England andWales). 2007. Accessed September 1, 2007
  • Danchin N, Blanchard D, Steg P G, et al. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 2004; 110: 1909–15
  • Stenestrand U, Lindback J, Wallentin L. Long-term outcome of primary percutaneous coronary intervention vs prehospital andin-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA 2006; 296: 1749–56
  • Lamfers E J, Schut A, Hertzberger D P, et al. Prehospital versus hospital fibrinolytic therapy using automated versus cardiologist electrocardiographic diagnosis of myocardial infarction: abortion of myocardial infarction andunjustified fibrinolytic therapy. Am Heart J 2004; 147: 509–15
  • Melchior T, Hallam D, Johansen B E. Aortic dissection in the thrombolytic era: early recognition andoptimal management is a prerequisite for increased survival. Int J Cardiol 1993; 42: 1–6
  • Gersh B J, Stone G W, White H D, Holmes D R, Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. JAMA 2005; 293: 979–86
  • Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825–9
  • Armstrong P W. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006; 27: 1530–8
  • Verheugt F W, Gersh B J, Armstrong P W. Aborted myocardial infarction: a new target for reperfusion therapy. Eur Heart J 2006; 27: 901–4
  • Dowdy L, Wagner G S, Birnbaum Y, et al. Aborted infarction: the ultimate myocardial salvage. Am Heart J 2004; 147: 390–4
  • Keeley E C, Grines C L. Should patients with acute myocardial infraction be transferred to a tertiary center for primary angioplasty or receive it at qualified hospitals in the community? The case for emergency transfer for primary percutaneous coronary intervention. Circulation 2005; 112: 3520–32
  • Nallamothu B K, Wang Y, Magid D J, et al. Relation between hospital specialization with primary percutaneous coronary intervention andclinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction-4 analysis. Circulation 2006; 113: 222–9
  • Epstein A J, Rathore S S, Volpp K G, Krumholz H M. Hospital percutaneous coronary intervention volume andpatient mortality, 1998 to 2000: does the evidence support current procedure volume minimums?. J Am Coll Cardiol 2004; 43: 1755–62
  • Canto J G, Every N R, Magid D J, et al. The volume of primary angioplasty procedures andsurvival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med 2000; 342: 1573–80
  • Wharton T P, Jr. Should patients with acute myocardial infraction be transferred to a tertiary center for primary angioplasty or receive it at qualified hospitals in community? The case for community hospital angioplasty. Circulation 2005; 112: 3509–20
  • de Villiers J S, Anderson T, McMeekin J D, Leung R C, Traboulsi M. Expedited transfer for primary percutaneous coronary intervention: a program evaluation. Can Med Assoc J 2007; 176: 1833–8
  • Henry T D, Unger B T, Sharkey S W, et al. Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention. Am Heart J 2005; 150: 373–84
  • Le May M R, So D Y, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2008; 358: 231–40
  • Quinn M J, Fitzgerald D J. Ticlopidine andclopidogrel. Circulation 1999; 100: 1667–72
  • Sabatine M S, Cannon C P, Gibson C M, et al. Addition of clopidogrel to aspirin andfibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89
  • Fox K A, Mehta S R, Peters R, et al. Benefits andrisks of the combination of clopidogrel andaspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202–8
  • Steinhubl S R, Berger P B, Mann J T, III, et al. Early andsustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–20
  • Verheugt F W, Montalescot G, Sabatine M S, et al. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis 2007; 23: 173–9
  • Jollis J G, Roettig M L, Aluko A O, et al. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 2007; 298: 2371–80

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.